Ai-designed antimicrobial peptides and peptide-drug conjugates
An AI-powered drug discovery platform that integrates proprietary silicon-based peptide chip technology with machine learning to identify and optimize antimicrobial peptides and peptide-drug conjugates. The solution offers a complete development pathway from computational candidate screening through to preclinical validation and commercial-scale manufacturing, currently evidenced by a pipeline that includes Phase I clinical-stage antimicrobial peptide candidates.
Overview\nThis AI-driven platform integrates proprietary silicon-based peptide chip technology with advanced machine learning to accelerate the discovery and optimization of novel antimicrobial peptides (AMPs) and peptide-drug conjugates (PDCs). By leveraging high-throughput data to train sophisticated AI models, the platform identifies optimal drug candidates with high precision, significantly reducing time-to-market for macromolecular therapeutics. Through a strategic CRDMO partnership, the platform supports end-to-end development—from initial computational screening and preclinical validation to API process optimization, formulation, regulatory filing, and large-scale commercial manufacturing.\n\n### Technical specifications\n- Proprietary InteraCtX digital molecular technology platform utilizing silicon-based peptide chips for high-throughput detection of protein interactions.\n- AI-powered computational screening and molecular optimization models capable of enhancing drug bioactivity, stability, and target specificity.\n- Demonstrated capability in generating broad-spectrum antimicrobial peptides, including candidates targeting multidrug-resistant bacteria with efficient MIC values (2-16µg/mL).\n- Specialized R&D for peptide-drug conjugates (PDCs) focused on precise delivery to tumor stroma and treatment of solid tumors.\n- Full-cycle CRDMO support provided via strategic industrial partnerships, covering formulation research, quality system establishment, and global regulatory compliance.\n\n### Technology readiness level\n6\n\nSupporting evidence: The platform has successfully transitioned from technical validation to clinical translation. The lead antimicrobial peptide candidate, iCAMP016, has received NMPA IND approval and is currently in Phase I clinical trials for the treatment of bacterial vaginosis. Other pipeline projects, such as the iCPDC-001 oncology project, have successfully completed preclinical candidate compound (PCC) screening and...
About iCarbonX Intelligent Peptide
iCarbonX Intelligent Peptide is a specialized pharmaceutical platform operating under the umbrella of iCarbonX. The company focuses on accelerating macromolecular drug development through a combination of proprietary silicon-based peptide chip technology and artificial intelligence. By utilizing high-throughput data to train and generate advanced AI drug discovery and optimization models, the platform facilitates the precise screening of drug candidate molecules, effectively improving drug bioactivity, stability, and targeting to meet evolving clinical transformation needs.
This technology serves as a significant tool for biopharmaceutical and biotechnology partners seeking to streamline the drug research and development process. By enabling efficient large-scale detection of protein interactions, the platform helps partners move rapidly from discovery to development. The company has engaged in strategic partnerships, including collaboration with Hybio Pharmaceutical, to advance innovative drug projects such as GLP-1R/GIPR/GCGR triple agonist peptides and other oncology-focused pipeline initiatives, demonstrating its potential to deliver best-in-class solutions for the pharmaceutical industry.
delivered to your inbox.